[1] Bjerre Knudsen L, Madsen LW, Andersen S, et al. Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation [J]. Endocrinology 2010; 151:1473–1486.
[2] Madsen LW, Knauf JA, Gotfredsen C, et al. GLP-1 receptor agonists and the thyroid: C-cell effects in mice are mediated via the GLP-1 receptor and not associated with RET activation [J]. Endocrinology 2012; 153:1538–1547.
[3] Alves C, Batel-Marques F, Macedo AF. A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer [J]. Diabetes Res Clin Pract. 2012;98(2):271-84.
[4] Hu W, Song R, Cheng R, et al. Use of GLP-1 Receptor Agonists and Occurrence of Thyroid Disorders: a Meta-Analysis of Randomized Controlled Trials [J]. Front Endocrinol (Lausanne). 2022;13:927859.
[5] Bezin et al. GLP-1 Receptor Agonists and the Risk of Thyroid Cancer [J]. Diabetes Care. 2023;46(2):384-390.
[6] Bea S, Son H, Bae JH, et al. Risk of thyroid cancer associated with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: A population-based cohort study [J]. Diabetes Obes Metab. 2023 Sep 21.
[7] Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 23-26 October 2023.
[8] Pasternak B, Wintzell V, Hviid A, et al. Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study. BMJ. 2024 Apr 10; 385:e078225.
[9] 《基层应用胰高糖素样肽-1受体激动剂治疗2型糖尿病的指导建议》专家组.基层应用胰高糖素样肽-1受体激动剂治疗2型糖尿病的指导建议[J].中国实用内科杂志,2023,43(1):32-38.
[10] 中华医学会内分泌学分会,中华医学会糖尿病学分会. 胰高糖素样肽-1 (GLP-1)受体激动剂用于治疗2型糖尿病的临床专家共识[J]. 中华内科杂志, 2020,59(11): 836-846.
